Author: "Wieten, L." - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Wieten, L."' showing total 227 results

Start Over Author "Wieten, L."

227 results on '"Wieten, L."'

1. SARS-CoV-2 cellular and humoral responses in vaccine-naive individuals during the first two waves of COVID-19 infections in the southern region of The Netherlands: a cross-sectional population-based study

Author: Hanssen, D. A. T., primary, Arts, K., additional, Nix, W. H. V., additional, Sweelssen, N. N. B., additional, Welbers, T. T. J., additional, de Theije, C., additional, Wieten, L., additional, Pagen, D. M. E., additional, Brinkhues, S., additional, Penders, J., additional, Dukers-Muijrers, N. H. T. M., additional, Hoebe, C. J. P. A., additional, Savelkoul, P. H. M., additional, and van Loo, I. H. M., additional
Published: 2024
Full Text: View/download PDF

2. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

Author: Ruggeri, A, de Wreede, L, Muller, C, Crivello, P, Bonneville, E, Petersdorf, E, Socie, G, Dubois, V, Niittyvuopio, R, Perasaari, J, Yakoub-Agha, I, Cornelissen, J, Wieten, L, Gedde-Dahl, T, Forcade, E, Crawley, C, Marsh, S, Gandemer, V, Tholouli, E, Bulabois, C, Huynh, A, Choi, G, Deconinck, E, Itala-Remes, M, Lenhoff, S, Bengtsson, M, Johansson, J, van Gorkom, G, Hoogenboom, J, Vago, L, Rocha, V, Bonini, C, Chabannon, C, Fleischhauer, K, Clausen, J, Holter, W, Kalhs, P, Beguin, Y, Bron, D, Deeren, D, Lung, W, Kerre, T, Poire, X, Selleslag, D, Schroyens, W, Jindra, P, Mayer, J, Vydra, J, Zak, P, Nielsen, B, Sengeloev, H, Kaare, A, Partanen, A, Bay, J, Bertrand, Y, Blaise, D, Bourhis, J, Chevallier, P, Cluzeau, T, Damaj, G, Fegueux, N, Guyotat, D, Hunault-Berger, M, Labussiere-Wallet, H, Leleu, X, Lioure, B, Maury, S, Michel, G, Mohty, M, Rubio, M, Tilly, H, Turlure, P, Bethge, W, Casper, J, Einsele, H, Ganser, A, Kroger, N, Martin, S, Platzbecker, U, Reinhardt, C, Schafer-Eckart, K, Thurner, L, Valerius, T, Wulf, G, Karakasis, D, Spyridonidis, A, Hauser, P, Remenyi, P, Reykdal, S, Mousavi, A, Angelucci, E, Arcese, W, Benedetti, F, Bernasconi, P, Biondi, A, Bonifazi, F, Carella, A, Carluccio, P, Casini, M, Cavanna, L, Ciceri, F, Cimino, G, Corradini, P, Fanin, R, Galieni, P, Grillo, G, Iori, A, La Nasa, G, Locatelli, F, Marotta, G, Martino, M, Mazza, P, Mordini, N, Musso, M, Olivieri, A, Pavone, V, Pane, F, Petrini, M, Pioltelli, P, Rambaldi, A, Ruggeri, M, Saccardi, R, Santarone, S, Scime, R, Sica, S, Tarella, C, Velardi, A, Visani, G, Zecca, M, Tanase, A, Kulagin, A, Savchenko, V, Lopez, C, Amor, A, Lopez, J, Caballero, D, Duarte, R, Cascon, M, Porras, R, Perez-Simon, J, Rovira, M, Sanz, J, Carrete, J, Cammenga, J, Isaksson, C, Mielke, S, Chalandon, Y, Passweg, J, Schanz, U, Meijer, E, Kuball, J, Veelken, J, Apperley, J, Bloor, A, Byrne, J, Carpenter, B, Clark, A, Collin, M, Craddock, C, Gibson, B, Khan, A, Martin, M, Medd, P, Nicholson, E, Orchard, K, Patel, A, Peniket, A, Potter, V, Snowden, J, Wilson, K, Ruggeri A., de Wreede L. C., Muller C. R., Crivello P., Bonneville E. F., Petersdorf E. W., Socie G., Dubois V., Niittyvuopio R., Perasaari J., Yakoub-Agha I., Cornelissen J. J., Wieten L., Gedde-Dahl T., Forcade E., Crawley C. R., Marsh S. G. E., Gandemer V., Tholouli E., Bulabois C. -E., Huynh A., Choi G., Deconinck E., Itala-Remes M., Lenhoff S., Bengtsson M., Johansson J. -E., van Gorkom G., Hoogenboom J. D., Vago L., Rocha V., Bonini C., Chabannon C., Fleischhauer K., Clausen J., Holter W., Kalhs P., Beguin Y., Bron D., Deeren D., Lung W. K., Kerre T., Poire X., Selleslag D., Schroyens W., Jindra P., Mayer J., Vydra J., Zak P., Nielsen B., Sengeloev H., Kaare A., Partanen A., Bay J., Bertrand Y., Blaise D., Bourhis J. H., Chevallier P., Cluzeau T., Damaj G., Fegueux N., Guyotat D., Hunault-Berger M., Labussiere-Wallet H., Leleu X., Lioure B., Maury S., Michel G., Mohty M., Rubio M. T., Tilly H., Turlure P., Bethge W., Casper J., Einsele H., Ganser A., Kroger N., Martin S., Platzbecker U., Reinhardt C., Schafer-Eckart K., Thurner L., Valerius T., Wulf G. G., Karakasis D., Spyridonidis A., Hauser P., Remenyi P., Reykdal S., Mousavi A., Angelucci E., Arcese W., Benedetti F., Bernasconi P., Biondi A., Bonifazi F., Carella A. M., Carluccio P., Casini M., Cavanna L., Ciceri F., Cimino G., Corradini P., Fanin R., Galieni P., Grillo G., Iori A. P., La Nasa G., Locatelli F., Marotta G., Martino M., Mazza P., Mordini N., Musso M., Olivieri A., Pavone V., Pane F., Petrini M., Pioltelli P., Rambaldi A., Ruggeri M., Saccardi R., Santarone S., Scime R., Sica S., Tarella C., Velardi A., Visani G., Zecca M., Tanase A., Kulagin A., Savchenko V., Lopez C. A., Amor A. A., Lopez J. L. B., Caballero D., Duarte R., Cascon M. J. P., Porras R. P., Perez-Simon J. A., Rovira M., Sanz J., Carrete J. P. T., Cammenga J., Isaksson C., Mielke S., Chalandon Y., Passweg J., Schanz U., Meijer E., Kuball J., Veelken J. H., Apperley J., Bloor A., Byrne J., Carpenter B., Clark A., Collin M., Craddock C., Gibson B. E., Khan A., Martin M., Medd P., Nicholson E., Orchard K., Patel A., Peniket A., Potter V., Snowden J., Wilson K. M. O., Ruggeri, A, de Wreede, L, Muller, C, Crivello, P, Bonneville, E, Petersdorf, E, Socie, G, Dubois, V, Niittyvuopio, R, Perasaari, J, Yakoub-Agha, I, Cornelissen, J, Wieten, L, Gedde-Dahl, T, Forcade, E, Crawley, C, Marsh, S, Gandemer, V, Tholouli, E, Bulabois, C, Huynh, A, Choi, G, Deconinck, E, Itala-Remes, M, Lenhoff, S, Bengtsson, M, Johansson, J, van Gorkom, G, Hoogenboom, J, Vago, L, Rocha, V, Bonini, C, Chabannon, C, Fleischhauer, K, Clausen, J, Holter, W, Kalhs, P, Beguin, Y, Bron, D, Deeren, D, Lung, W, Kerre, T, Poire, X, Selleslag, D, Schroyens, W, Jindra, P, Mayer, J, Vydra, J, Zak, P, Nielsen, B, Sengeloev, H, Kaare, A, Partanen, A, Bay, J, Bertrand, Y, Blaise, D, Bourhis, J, Chevallier, P, Cluzeau, T, Damaj, G, Fegueux, N, Guyotat, D, Hunault-Berger, M, Labussiere-Wallet, H, Leleu, X, Lioure, B, Maury, S, Michel, G, Mohty, M, Rubio, M, Tilly, H, Turlure, P, Bethge, W, Casper, J, Einsele, H, Ganser, A, Kroger, N, Martin, S, Platzbecker, U, Reinhardt, C, Schafer-Eckart, K, Thurner, L, Valerius, T, Wulf, G, Karakasis, D, Spyridonidis, A, Hauser, P, Remenyi, P, Reykdal, S, Mousavi, A, Angelucci, E, Arcese, W, Benedetti, F, Bernasconi, P, Biondi, A, Bonifazi, F, Carella, A, Carluccio, P, Casini, M, Cavanna, L, Ciceri, F, Cimino, G, Corradini, P, Fanin, R, Galieni, P, Grillo, G, Iori, A, La Nasa, G, Locatelli, F, Marotta, G, Martino, M, Mazza, P, Mordini, N, Musso, M, Olivieri, A, Pavone, V, Pane, F, Petrini, M, Pioltelli, P, Rambaldi, A, Ruggeri, M, Saccardi, R, Santarone, S, Scime, R, Sica, S, Tarella, C, Velardi, A, Visani, G, Zecca, M, Tanase, A, Kulagin, A, Savchenko, V, Lopez, C, Amor, A, Lopez, J, Caballero, D, Duarte, R, Cascon, M, Porras, R, Perez-Simon, J, Rovira, M, Sanz, J, Carrete, J, Cammenga, J, Isaksson, C, Mielke, S, Chalandon, Y, Passweg, J, Schanz, U, Meijer, E, Kuball, J, Veelken, J, Apperley, J, Bloor, A, Byrne, J, Carpenter, B, Clark, A, Collin, M, Craddock, C, Gibson, B, Khan, A, Martin, M, Medd, P, Nicholson, E, Orchard, K, Patel, A, Peniket, A, Potter, V, Snowden, J, Wilson, K, Ruggeri A., de Wreede L. C., Muller C. R., Crivello P., Bonneville E. F., Petersdorf E. W., Socie G., Dubois V., Niittyvuopio R., Perasaari J., Yakoub-Agha I., Cornelissen J. J., Wieten L., Gedde-Dahl T., Forcade E., Crawley C. R., Marsh S. G. E., Gandemer V., Tholouli E., Bulabois C. -E., Huynh A., Choi G., Deconinck E., Itala-Remes M., Lenhoff S., Bengtsson M., Johansson J. -E., van Gorkom G., Hoogenboom J. D., Vago L., Rocha V., Bonini C., Chabannon C., Fleischhauer K., Clausen J., Holter W., Kalhs P., Beguin Y., Bron D., Deeren D., Lung W. K., Kerre T., Poire X., Selleslag D., Schroyens W., Jindra P., Mayer J., Vydra J., Zak P., Nielsen B., Sengeloev H., Kaare A., Partanen A., Bay J., Bertrand Y., Blaise D., Bourhis J. H., Chevallier P., Cluzeau T., Damaj G., Fegueux N., Guyotat D., Hunault-Berger M., Labussiere-Wallet H., Leleu X., Lioure B., Maury S., Michel G., Mohty M., Rubio M. T., Tilly H., Turlure P., Bethge W., Casper J., Einsele H., Ganser A., Kroger N., Martin S., Platzbecker U., Reinhardt C., Schafer-Eckart K., Thurner L., Valerius T., Wulf G. G., Karakasis D., Spyridonidis A., Hauser P., Remenyi P., Reykdal S., Mousavi A., Angelucci E., Arcese W., Benedetti F., Bernasconi P., Biondi A., Bonifazi F., Carella A. M., Carluccio P., Casini M., Cavanna L., Ciceri F., Cimino G., Corradini P., Fanin R., Galieni P., Grillo G., Iori A. P., La Nasa G., Locatelli F., Marotta G., Martino M., Mazza P., Mordini N., Musso M., Olivieri A., Pavone V., Pane F., Petrini M., Pioltelli P., Rambaldi A., Ruggeri M., Saccardi R., Santarone S., Scime R., Sica S., Tarella C., Velardi A., Visani G., Zecca M., Tanase A., Kulagin A., Savchenko V., Lopez C. A., Amor A. A., Lopez J. L. B., Caballero D., Duarte R., Cascon M. J. P., Porras R. P., Perez-Simon J. A., Rovira M., Sanz J., Carrete J. P. T., Cammenga J., Isaksson C., Mielke S., Chalandon Y., Passweg J., Schanz U., Meijer E., Kuball J., Veelken J. H., Apperley J., Bloor A., Byrne J., Carpenter B., Clark A., Collin M., Craddock C., Gibson B. E., Khan A., Martin M., Medd P., Nicholson E., Orchard K., Patel A., Peniket A., Potter V., Snowden J., and Wilson K. M. O.
Published: 2023

3. Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant

Author: Kamburova, E.G., Wisse, B.W., Joosten, I., Allebes, W.A., van der Meer, A., Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., van Reekum, F.E., van Zuilen, A.D., Verhaar, M.C., Bots, M.L., Drop, A.C.A.D., Plaisier, L., Seelen, M.A.J., Sanders, J.S.F., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G.J., Voorter, C.E., Wieten, L., van Duijnhoven, E.M., Gelens, M., Christiaans, M.H.L., van Ittersum, F.J., Nurmohamed, S.A., Lardy, N.M., Swelsen, W., van der Pant, K.A., van der Weerd, N.C., ten Berge, I.J.M., Bemelman, F.J., Hoitsma, A., van der Boog, P.J.M., de Fijter, J.W., Betjes, M.G.H., Heidt, S., Roelen, D.L., Claas, F.H., and Otten, H.G.
Published: 2018
Full Text: View/download PDF

4. Evaluation of 19years of international external proficiency testing for high-resolution HLA typing.

Author: Voorter, C. E. M., Groeneveld, L., Heidt, S., and Wieten, L.
Subjects: EUROPEAN integration, IMMUNOGENETICS, TESTING laboratories, ALLELES, LEUCOCYTES, TANDEM repeats
Abstract: The international high-resolution external proficiency testing (EPT) started in 2004 with high-resolution typing of human leucocyte antigen (HLA) class I (HLA-A,B,C) and HLA class II (HLA-DRB1, DRB345, DQB1, and DPB1) alleles, since possibilities for such an EPT within Europe were limited and all existing EPTs at that time made use of the comparison of HLA typing results without a reference. This EPT was set up as a collaboration between the HLA laboratory of Leiden, providing DNA samples to the participants, and the laboratory of Maastricht, performing the high-resolution typing as the reference result and evaluating the results of all participants according to the prevailing European Federation for Immunogenetics (EFI) standards. Once a year, 12 samples were sent to the participating laboratories, and evaluation and certificates were provided at the end of that same year. During the years, the EPT was extended to lowresolution HLA class I and II typing, high-resolution typing including DQA1 and DPA1, and allelic resolution typing for HLA class I, the latter one being unique in this field. Evaluation of the high-resolution typing results of the last 19 years showed a clear increase in the number of loci tested by the participating laboratories and a clear change of method from Sanger sequencing with additional other techniques (SSO/SSP) to the nowadays widely used nextgeneration sequencing method. By strictly using the EFI rules for highresolution HLA typing, the participants were made aware of the ambiguities within exons 2 and 3 for class I and exon 2 for class II and the presence of null alleles even in a two-field HLA typing. There was an impressive learning curve, resulting in >98% correctly typed samples since 2017 and a 100% fulfillment of EFI rules for all laboratories for all loci submitted in the last 2 years. Overall, this EPT meets the need of an EPT for high-resolution typing for EFI accreditation. [ABSTRACT FROM AUTHOR]
Published: 2024
Full Text: View/download PDF

5. PO-2242 HDR-brachytherapy increases PD-L-1 immune expression on prostate cancer (NCT04247217)

Author: Vanneste, B., primary, Van Limbergen, E., additional, Dubois, L., additional, Wieten, L., additional, Aarts, M., additional, Van Roermund, J., additional, Marcelissen, T., additional, Li, X., additional, Samarasks, I., additional, and De Ruysscher, D., additional
Published: 2023
Full Text: View/download PDF

6. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

Author: Ruggeri, A., de Wreede, L. C., Muller, C. R., Crivello, P., Bonneville, E. F., Petersdorf, E. W., Socie, G., Dubois, V., Niittyvuopio, R., Perasaari, J., Yakoub-Agha, I., Cornelissen, J. J., Wieten, L., Gedde-Dahl, T., Forcade, E., Crawley, C. R., Marsh, S. G. E., Gandemer, V., Tholouli, E., Bulabois, C. -E., Huynh, A., Choi, G., Deconinck, E., Itala-Remes, M., Lenhoff, S., Bengtsson, M., Johansson, J. -E., van Gorkom, G., Hoogenboom, J. D., Vago, L., Rocha, V., Bonini, C., Chabannon, C., Fleischhauer, K., Clausen, J., Holter, W., Kalhs, P., Beguin, Y., Bron, D., Deeren, D., Lung, W. K., Kerre, T., Poire, X., Selleslag, D., Schroyens, W., Jindra, P., Mayer, J., Vydra, J., Zak, P., Nielsen, B., Sengeloev, H., Kaare, A., Partanen, A., Bay, J., Bertrand, Y., Blaise, D., Bourhis, J. H., Chevallier, P., Cluzeau, T., Damaj, G., Fegueux, N., Guyotat, D., Hunault-Berger, M., Labussiere-Wallet, H., Leleu, X., Lioure, B., Maury, S., Michel, G., Mohty, M., Rubio, M. T., Tilly, H., Turlure, P., Bethge, W., Casper, J., Einsele, H., Ganser, A., Kroger, N., Martin, S., Platzbecker, U., Reinhardt, C., Schafer-Eckart, K., Thurner, L., Valerius, T., Wulf, G. G., Karakasis, D., Spyridonidis, A., Hauser, P., Remenyi, P., Reykdal, S., Mousavi, A., Angelucci, E., Arcese, W., Benedetti, F., Bernasconi, P., Biondi, A., Bonifazi, F., Carella, A. M., Carluccio, P., Casini, M., Cavanna, L., Ciceri, F., Cimino, G., Corradini, P., Fanin, R., Galieni, P., Grillo, G., Iori, A. P., La Nasa, G., Locatelli, Franco, Marotta, G., Martino, M., Mazza, P., Mordini, N., Musso, M., Olivieri, A., Pavone, V., Pane, F., Petrini, M., Pioltelli, P., Rambaldi, A., Ruggeri, M., Saccardi, R., Santarone, S., Scime, R., Sica, S., Tarella, C., Velardi, A., Visani, G., Zecca, M., Tanase, A., Kulagin, A., Savchenko, V., Lopez, C. A., Amor, A. A., Lopez, J. L. B., Caballero, D., Duarte, R., Cascon, M. J. P., Porras, R. P., Perez-Simon, J. A., Rovira, M., Sanz, J., Carrete, J. P. T., Cammenga, J., Isaksson, C., Mielke, S., Chalandon, Y., Passweg, J., Schanz, U., Meijer, E., Kuball, J., Veelken, J. H., Apperley, J., Bloor, A., Byrne, J., Carpenter, B., Clark, A., Collin, M., Craddock, C., Gibson, B. E., Khan, A., Martin, M., Medd, P., Nicholson, E., Orchard, K., Patel, A., Peniket, A., Potter, V., Snowden, J., Wilson, K. M. O., Locatelli F. (ORCID:0000-0002-7976-3654), Ruggeri, A., de Wreede, L. C., Muller, C. R., Crivello, P., Bonneville, E. F., Petersdorf, E. W., Socie, G., Dubois, V., Niittyvuopio, R., Perasaari, J., Yakoub-Agha, I., Cornelissen, J. J., Wieten, L., Gedde-Dahl, T., Forcade, E., Crawley, C. R., Marsh, S. G. E., Gandemer, V., Tholouli, E., Bulabois, C. -E., Huynh, A., Choi, G., Deconinck, E., Itala-Remes, M., Lenhoff, S., Bengtsson, M., Johansson, J. -E., van Gorkom, G., Hoogenboom, J. D., Vago, L., Rocha, V., Bonini, C., Chabannon, C., Fleischhauer, K., Clausen, J., Holter, W., Kalhs, P., Beguin, Y., Bron, D., Deeren, D., Lung, W. K., Kerre, T., Poire, X., Selleslag, D., Schroyens, W., Jindra, P., Mayer, J., Vydra, J., Zak, P., Nielsen, B., Sengeloev, H., Kaare, A., Partanen, A., Bay, J., Bertrand, Y., Blaise, D., Bourhis, J. H., Chevallier, P., Cluzeau, T., Damaj, G., Fegueux, N., Guyotat, D., Hunault-Berger, M., Labussiere-Wallet, H., Leleu, X., Lioure, B., Maury, S., Michel, G., Mohty, M., Rubio, M. T., Tilly, H., Turlure, P., Bethge, W., Casper, J., Einsele, H., Ganser, A., Kroger, N., Martin, S., Platzbecker, U., Reinhardt, C., Schafer-Eckart, K., Thurner, L., Valerius, T., Wulf, G. G., Karakasis, D., Spyridonidis, A., Hauser, P., Remenyi, P., Reykdal, S., Mousavi, A., Angelucci, E., Arcese, W., Benedetti, F., Bernasconi, P., Biondi, A., Bonifazi, F., Carella, A. M., Carluccio, P., Casini, M., Cavanna, L., Ciceri, F., Cimino, G., Corradini, P., Fanin, R., Galieni, P., Grillo, G., Iori, A. P., La Nasa, G., Locatelli, Franco, Marotta, G., Martino, M., Mazza, P., Mordini, N., Musso, M., Olivieri, A., Pavone, V., Pane, F., Petrini, M., Pioltelli, P., Rambaldi, A., Ruggeri, M., Saccardi, R., Santarone, S., Scime, R., Sica, S., Tarella, C., Velardi, A., Visani, G., Zecca, M., Tanase, A., Kulagin, A., Savchenko, V., Lopez, C. A., Amor, A. A., Lopez, J. L. B., Caballero, D., Duarte, R., Cascon, M. J. P., Porras, R. P., Perez-Simon, J. A., Rovira, M., Sanz, J., Carrete, J. P. T., Cammenga, J., Isaksson, C., Mielke, S., Chalandon, Y., Passweg, J., Schanz, U., Meijer, E., Kuball, J., Veelken, J. H., Apperley, J., Bloor, A., Byrne, J., Carpenter, B., Clark, A., Collin, M., Craddock, C., Gibson, B. E., Khan, A., Martin, M., Medd, P., Nicholson, E., Orchard, K., Patel, A., Peniket, A., Potter, V., Snowden, J., Wilson, K. M. O., and Locatelli F. (ORCID:0000-0002-7976-3654)
Abstract: NO ABSTRACT
Published: 2023

7. Somatic mutations in hematological tumors can interfere with accurate HLA and chimerism diagnostics

Author: Olieslagers, T., van Gorkom, G., Beckers, E., Wieten, L., Voorter, C., RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Transplant. Immunology/Tissue Typing lab, Interne Geneeskunde, MUMC+: MA Hematologie (9), RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation, and MUMC+: DA TI Staf (9)
Published: 2022

8. New insights in HLA‐E polymorphism by refined analysis of the full‐length gene

Author: Olieslagers, T. I., Voorter, C. E. M., Groeneweg, M., Xu, Y., Wieten, L., and Tilanus, M. G. J.
Published: 2017
Full Text: View/download PDF

9. P1570: SARS-COV-2 HUMORAL AND CELLULAR VACCINATION RESPONSE IN PATIENTS WITH LYMPHOID HAEMATOLOGICAL MALIGNANCIES

Author: Boerenkamp, L. S., primary, Pothast, C. R., additional, Dijkland, R. C., additional, van Loo, I. H., additional, Wieten, L., additional, Halkes, C. J., additional, Heemskerk, M. H., additional, and Van Elssen, C. H., additional
Published: 2022
Full Text: View/download PDF

10. The role of gene polymorphism in HLA class I splicing

Author: Voorter, C. E. M., Gerritsen, K. E. H., Groeneweg, M., Wieten, L., and Tilanus, M. G. J.
Published: 2016
Full Text: View/download PDF

11. Beneficial role of CD8+T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias

Author: Bondanza, A., Ruggeri, L., Noviello, M., Eikema, D.J., Bonini, C., Chabannon, C., Werf, S. van der, Biezen, A. van, Wreede, L.C. de, Crucitti, L., Vago, L., Merluzzi, M., Massei, M.S., Veelken, H., Koc, Y., Bader, P., Gruhn, B., Locatelli, F., Ciceri, F., Toubert, A., Velardi, A., Bernardo, M.E., Dazzi, F., Ellard, R., Fleischhauer, K., Greco, R., Hudecek, M., Kohl, U., Kuball, J., Malard, F., Pedrazzoli, P., Rocha, V., Ruggeri, A., Urbano-Ispizua, A., Wang, J.F., Wieten, L., EBMT Cell Therapy Immunobiol Worki, Bondanza, Attilio, Ruggeri, Loredana, Noviello, Maddalena, Eikema, Dirk-Jan, Bonini, Chiara, Chabannon, Christian, van der Werf, Steffie, van Biezen, Anja, de Wreede, Liesbeth C., Crucitti, Lara, Vago, Luca, Merluzzi, Mara, Massei, Maria Speranza, Veelken, Hendrik, Koc, Yener, Bader, Peter, Gruhn, Bernd, Locatelli, Franco, Ciceri, Fabio, Toubert, Antoine, Velardi, Andrea, MUMC+: DA TI Laboratorium (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, and MUMC+: DA TI Staf (9)
Subjects: Male, Oncology, BLOOD, COUNT, Medizin, CHILDREN, CD8-Positive T-Lymphocytes, DISEASE, 0302 clinical medicine, Risk Factors, hemic and lymphatic diseases, Cytotoxic T cell, Registries, Child, INDEX, Leukemia, Hematology, Middle Aged, RECOVERY, Haematopoiesis, surgical procedures, operative, medicine.anatomical_structure, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, Transplantation, Child, Preschool, 030220 oncology & carcinogenesis, HSCT, Female, Stem cell, Adult, medicine.medical_specialty, Adolescent, T cell, Human leukocyte antigen, Young Adult, 03 medical and health sciences, CD8-positive T-lymphocytes, haematopoietic stem cell transplantation, risk factors, Internal medicine, SCORE, medicine, Humans, IMMUNOTHERAPY, Aged, business.industry, ADULTS, BONE-MARROW-TRANSPLANTATION, Transplantation, Haploidentical, business, CD8, Stem Cell Transplantation, 030215 immunology, RESPONSES
Abstract: HLA-haploidentical haematopoietic stem cell transplantation (haplo-HSCT) is increasingly offered to patients with high-risk acute leukaemia. Unfortunately, haplo-HSCT is followed by a delayed immunoreconstitution. The aim of this EBMT registry study was to explore the clinical impact of lymphocyte subset counts after haplo-HSCT. We considered 144 leukaemic patients transplanted in the period 2001-2012. Pre-transplantation clinical variables and differential immune-cell counts (CD3, CD4, CD8 T cells, NK and B cells) measured before day 100 were evaluated for their capacity to predict overall survival, relapse mortality or non-relapse mortality (NRM). Negative prognostic factors for overall survival were advanced disease state at transplantation, host age and CMV seropositivity. Higher CD3, CD4 and CD8 counts were associated with a better overall survival and a lower NRM. Strikingly, when tested in multivariable analysis, higher CD3 and CD8 counts were still significantly associated with a lower NRM. These results indicate that an accelerated T-cell reconstitution correlates with less transplantation mortality, likely due to the protective role of T cells against viral infections. This observation suggests that CD8+ T-cell counts should be investigated as surrogate biomarkers of outcome in prospective haplo-HSCT trials.
Published: 2019
Full Text: View/download PDF

12. Peptide-induced HLA-E expression in human PBMCs is dependent on peptide sequence and the HLA-E genotype

Author: Lauterbach, N., Wieten, L., Popeijus, H. E., Vanderlocht, J., van Zon, P. M. H., Voorter, C. E. M., and Tilanus, M. G. J.
Published: 2015
Full Text: View/download PDF

13. T-Cell Epitopes Shared Between Immunizing HLA and Donor HLA Associate With Graft Failure After Kidney Transplantation

Author: Peereboom, E.T.M., Matern, B.M., Tomosugi, T., Niemann, M., Drylewicz, J., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Reekum, F.E. van, Verhaar, M.C., Kamburova, E.G., Seelen, M.A., Sanders, J.S., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H., Ittersum, F.J. van, Nurmohamed, A., Lardy, N.M., Swelsen, W., Pant, Karlijn A.M.I. van der, Weerd, N.C. van der, Berge, I.J. Ten, Bemelman, F.J., Vries, A.P.J de, Fijter, J.W. de, Betjes, M. G. H., Roelen, D.L., Claas, F.H.J., Otten, H.G., Heidt, S., Zuilen, A.D. van, Kobayashi, T., Geneugelijk, K., Spierings, E, Peereboom, E.T.M., Matern, B.M., Tomosugi, T., Niemann, M., Drylewicz, J., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Reekum, F.E. van, Verhaar, M.C., Kamburova, E.G., Seelen, M.A., Sanders, J.S., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H., Ittersum, F.J. van, Nurmohamed, A., Lardy, N.M., Swelsen, W., Pant, Karlijn A.M.I. van der, Weerd, N.C. van der, Berge, I.J. Ten, Bemelman, F.J., Vries, A.P.J de, Fijter, J.W. de, Betjes, M. G. H., Roelen, D.L., Claas, F.H.J., Otten, H.G., Heidt, S., Zuilen, A.D. van, Kobayashi, T., Geneugelijk, K., and Spierings, E
Abstract: Contains fulltext : 241482.pdf (Publisher’s version ) (Open Access), CD4(+) T-helper cells play an important role in alloimmune reactions following transplantation by stimulating humoral as well as cellular responses, which might lead to failure of the allograft. CD4(+) memory T-helper cells from a previous immunizing event can potentially be reactivated by exposure to HLA mismatches that share T-cell epitopes with the initial immunizing HLA. Consequently, reactivity of CD4(+) memory T-helper cells toward T-cell epitopes that are shared between immunizing HLA and donor HLA could increase the risk of alloimmunity following transplantation, thus affecting transplant outcome. In this study, the amount of T-cell epitopes shared between immunizing and donor HLA was used as a surrogate marker to evaluate the effect of donor-reactive CD4(+) memory T-helper cells on the 10-year risk of death-censored kidney graft failure in 190 donor/recipient combinations using the PIRCHE-II algorithm. The T-cell epitopes of the initial theoretical immunizing HLA and the donor HLA were estimated and the number of shared PIRCHE-II epitopes was calculated. We show that the natural logarithm-transformed PIRCHE-II overlap score, or Shared T-cell EPitopes (STEP) score, significantly associates with the 10-year risk of death-censored kidney graft failure, suggesting that the presence of pre-transplant donor-reactive CD4(+) memory T-helper cells might be a strong indicator for the risk of graft failure following kidney transplantation.
Published: 2021

14. Clinical and immunological significance of HLA-E in stem cell transplantation and cancer

Author: Wieten, L., Mahaweni, N. M., Voorter, C. E.M., Bos, G. M.J., and Tilanus, M. G.J.
Published: 2014
Full Text: View/download PDF

15. ALLOREACTIVE NK CELL THERAPY IN THE RAG2-/-C-/- MULTIPLE MYELOMA MODEL: PH-P537

Author: Bos, G., Sarkar, S., Wieten, L., Martens, A., Noort, W., and Groen, R.
Published: 2014

16. Full-length HLA-DPB1 diversity in multiple alleles of individuals from Caucasian, Black, or Oriental origin

Author: Lauterbach, N., Voorter, C. E. M., Stallinga, C. M. H. A., Groeneweg, M., Wieten, L., and Tilanus, M. G. J.
Published: 2012
Full Text: View/download PDF

17. HLA expression influences susceptibility of multiple myeloma cells to elimination by NK cells: O14

Author: Wieten, L., van Elssen, J. H.M. J., Sarkar, S., Martens, A. C. M., Bos, G. M. J., and Tilanus, M. G. J.
Published: 2011

18. Immunotherapy as sensitizer for local radiotherapy

Author: Vanneste, Ben G.L., primary, Van Limbergen, Evert J, additional, Dubois, Ludwig, additional, Samarska, Iryna V., additional, Wieten, L., additional, Aarts, M. J.B., additional, Marcelissen, T., additional, and De Ruysscher, Dirk, additional
Published: 2020
Full Text: View/download PDF

19. Heat shock proteins induce T cell regulation of chronic inflammation

Author: Hauet-Broere, F, Wieten, L, Guichelaar, T, Berlo, S, van der Zee, R, and Van Eden, W
Published: 2006

20. Toward a Sensible Single-antigen Bead Cutoff Based on Kidney Graft Survival

Author: Wisse, B.W., Kamburova, E.G., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., Reekum, F.E. van, Zuilen, A.D. van, Verhaar, M.C., Bots, M.L., Drop, A., Plaisier, L., Seelen, M.A., Stephan Sanders, J., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., van Duijnhoven, E.M., Gelens, M., Christiaans, M.H., van Ittersum, F.J., Nurmohamed, S.A., Lardy, N.M., Swelsen, W., Pant, K. van der, Weerd, N.C. van der, Berge, I.J. ten, Bemelman, F.J., Hoitsma, A.J., Boog, P.J. van der, Fijter, J.W. de, Betjes, M.G., Heidt, S., Roelen, D.L., Claas, F.H., Otten, H.G., Wisse, B.W., Kamburova, E.G., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., Reekum, F.E. van, Zuilen, A.D. van, Verhaar, M.C., Bots, M.L., Drop, A., Plaisier, L., Seelen, M.A., Stephan Sanders, J., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., van Duijnhoven, E.M., Gelens, M., Christiaans, M.H., van Ittersum, F.J., Nurmohamed, S.A., Lardy, N.M., Swelsen, W., Pant, K. van der, Weerd, N.C. van der, Berge, I.J. ten, Bemelman, F.J., Hoitsma, A.J., Boog, P.J. van der, Fijter, J.W. de, Betjes, M.G., Heidt, S., Roelen, D.L., Claas, F.H., and Otten, H.G.
Abstract: Contains fulltext : 204258.pdf (publisher's version ) (Open Access), BACKGROUND: There is no consensus in the literature on the interpretation of single-antigen bead positive for a specific HLA antibody. METHODS: To inform the debate, we studied the relationship between various single-antigen bead positivity algorithms and the impact of resulting donor-specific HLA antibody (DSA) positivity on long-term kidney graft survival in 3237 deceased-donor transplants. RESULTS: First, we showed that the interassay variability can be greatly reduced when working with signal-to-background ratios instead of absolute median fluorescence intensities (MFIs). Next, we determined pretransplant DSA using various MFI cutoffs, signal-to-background ratios, and combinations thereof. The impact of the various cutoffs was studied by comparing the graft survival between the DSA-positive and DSA-negative groups. We did not observe a strong impact of various cutoff levels on 10-year graft survival. A stronger relationship between the cutoff level and 1-year graft survival for DSA-positive transplants was found when using signal-to-background ratios, most pronounced for the bead of the same HLA locus with lowest MFI taken as background. CONCLUSIONS: With respect to pretransplant risk stratification, we propose a signal-to-background ratio-6 (using the bead of the same HLA-locus with lowest MFI as background) cutoff of 15 combined with an MFI cutoff of 500, resulting in 8% and 21% lower 1- and 10-year graft survivals, respectively, for 8% DSA-positive transplants.
Published: 2019

21. Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients

Author: Heidt, S., Haasnoot, G.W., Witvliet, M.D., Linden-van Oevelen, M.J.H. van der, Kamburova, E.G., Wisse, B.W., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., Reekum, F.E. van, Zuilen, A.D. van, Verhaar, M.C., Bots, M.L., Drop, A., Plaisier, L., Seelen, M.A., Sanders, J.S., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H., Ittersum, F.J. van, Nurmohamed, S.A., Lardy, N.M., Swelsen, W., Pant, K. van der, Weerd, N.C. van der, Berge, I.J. Ten, Bemelman, F.J., Hoitsma, A., Boog, P.J. van der, Fijter, J.W. de, Betjes, M.G., Otten, H.G., Roelen, D.L., Claas, F.H., Heidt, S., Haasnoot, G.W., Witvliet, M.D., Linden-van Oevelen, M.J.H. van der, Kamburova, E.G., Wisse, B.W., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., Reekum, F.E. van, Zuilen, A.D. van, Verhaar, M.C., Bots, M.L., Drop, A., Plaisier, L., Seelen, M.A., Sanders, J.S., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H., Ittersum, F.J. van, Nurmohamed, S.A., Lardy, N.M., Swelsen, W., Pant, K. van der, Weerd, N.C. van der, Berge, I.J. Ten, Bemelman, F.J., Hoitsma, A., Boog, P.J. van der, Fijter, J.W. de, Betjes, M.G., Otten, H.G., Roelen, D.L., and Claas, F.H.
Abstract: Contains fulltext : 208426.pdf (publisher's version ) (Open Access), Whereas regular allocation avoids unacceptable mismatches on the donor organ, allocation to highly sensitized patients within the Eurotransplant Acceptable Mismatch (AM) program is based on the patient's HLA phenotype plus acceptable antigens. These are HLA antigens to which the patient never made antibodies, as determined by extensive laboratory testing. AM patients have superior long-term graft survival compared with highly sensitized patients in regular allocation. Here, we questioned whether the AM program also results in lower rejection rates. From the PROCARE cohort, consisting of all Dutch kidney transplants in 1995-2005, we selected deceased donor single transplants with a minimum of 1 HLA mismatch and determined the cumulative 6-month rejection incidence for patients in AM or regular allocation. Additionally, we determined the effect of minimal matching criteria of 1 HLA-B plus 1 HLA-DR, or 2 HLA-DR antigens on rejection incidence. AM patients showed significantly lower rejection rates than highly immunized patients in regular allocation, comparable to nonsensitized patients, independent of other risk factors for rejection. In contrast to highly sensitized patients in regular allocation, minimal matching criteria did not affect rejection rates in AM patients. Allocation based on acceptable antigens leads to relatively low-risk transplants for highly sensitized patients with rejection rates similar to those of nonimmunized individuals.
Published: 2019

22. A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival

Author: Michielsen, L.A., Wisse, B.W., Kamburova, E.G., Verhaar, M.C., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E, Hack, C.E., Reekum, F.E. van, Bots, M.L., Drop, A., Plaisier, L., Seelen, M.A., Sanders, J.F., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H., Ittersum, F.J. van, Nurmohamed, S.A., Lardy, N.M., Swelsen, W., Pant, K.A. van der, Weerd, N.C. van der, Berge, I.J. ten, Bemelman, F.J., Hoitsma, A.J., Boog, P.J. van der, Fijter, J.W. de, Betjes, M.G., Heidt, S., Roelen, D.L., Claas, F.H., Otten, H.G., Zuilen, A.D. van, Michielsen, L.A., Wisse, B.W., Kamburova, E.G., Verhaar, M.C., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E, Hack, C.E., Reekum, F.E. van, Bots, M.L., Drop, A., Plaisier, L., Seelen, M.A., Sanders, J.F., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H., Ittersum, F.J. van, Nurmohamed, S.A., Lardy, N.M., Swelsen, W., Pant, K.A. van der, Weerd, N.C. van der, Berge, I.J. ten, Bemelman, F.J., Hoitsma, A.J., Boog, P.J. van der, Fijter, J.W. de, Betjes, M.G., Heidt, S., Roelen, D.L., Claas, F.H., Otten, H.G., and Zuilen, A.D. van
Abstract: Item does not contain fulltext, BACKGROUND: Pre-transplant donor-specific anti-human leucocyte antigen (HLA) antibodies (DSAs) are associated with impaired kidney graft survival while the clinical relevance of non-donor-specific anti-HLA antibodies (nDSAs) is more controversial. The aim of the present paired kidney graft study was to compare the clinical relevance of DSAs and nDSAs. METHODS: To eliminate donor and era-dependent factors, a post hoc paired kidney graft analysis was performed as part of a Dutch multicentre study evaluating all transplantations between 1995 and 2005 with available pre-transplant serum samples. Anti-HLA antibodies were detected with a Luminex single-antigen bead assay. RESULTS: Among 3237 deceased donor transplantations, we identified 115 recipient pairs receiving a kidney from the same donor with one recipient being DSA positive and the other without anti-HLA antibodies. Patients with pre-transplant DSAs had a significantly lower 10-year death-censored graft survival (55% versus 82%, P=0.0001). We identified 192 pairs with one recipient as nDSA positive (against Class I and/or II) and the other without anti-HLA antibodies. For the patients with nDSAs against either Class I or II, graft survival did not significantly differ compared with patients without anti-HLA antibodies (74% versus 77%, P = 0.79). Only in patients with both nDSAs Class I and II was there a trend towards a lower graft survival (58%, P = 0.06). Lastly, in a small group of 42 recipient pairs, 10-year graft survival in recipients with DSAs was 49% compared with 68% in recipients with nDSAs (P=0.11). CONCLUSION: This paired kidney analysis confirms that the presence of pre-transplant DSAs in deceased donor transplantations is a risk marker for graft loss, whereas nDSAs in general are not associated with a lower graft survival. Subgroup analysis indicated that only in broadly sensitized patients with nDSAs against Class I and II, nDSAs may be a risk marker for graft loss in the long term.
Published: 2019

23. Antibodies against ARHGDIB are associated with long-term kidney graft loss

Author: Kamburova, E.G., Gruijters, M.L., Kardol-Hoefnagel, T., Wisse, B.W., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., Reekum, F.E. van, Zuilen, A.D. van, Verhaar, M.C., Bots, M.L., Drop, A., Plaisier, L., Melchers, R.C., Seelen, M.A., Sanders, J.S., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H., Ittersum, F.J. van, Nurmohamed, S.A., Lardy, N.M., Swelsen, W., Pant, K. van der, Weerd, N.C. van der, Berge, I.J. Ten, Hoitsma, A., Boog, P.J. van der, Fijter, J.W. de, Betjes, M.G., Heidt, S., Roelen, D.L., Claas, F.H., Bemelman, F.J., Otten, H.G., Kamburova, E.G., Gruijters, M.L., Kardol-Hoefnagel, T., Wisse, B.W., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., Reekum, F.E. van, Zuilen, A.D. van, Verhaar, M.C., Bots, M.L., Drop, A., Plaisier, L., Melchers, R.C., Seelen, M.A., Sanders, J.S., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H., Ittersum, F.J. van, Nurmohamed, S.A., Lardy, N.M., Swelsen, W., Pant, K. van der, Weerd, N.C. van der, Berge, I.J. Ten, Hoitsma, A., Boog, P.J. van der, Fijter, J.W. de, Betjes, M.G., Heidt, S., Roelen, D.L., Claas, F.H., Bemelman, F.J., and Otten, H.G.
Abstract: Contains fulltext : 215571.pdf (publisher's version ) (Open Access), The clinical significance of non-HLA antibodies on renal allograft survival is a matter of debate, due to differences in reported results and lack of large-scale studies incorporating analysis of multiple non-HLA antibodies simultaneously. We developed a multiplex non-HLA antibody assay against 14 proteins highly expressed in the kidney. In this study, the presence of pretransplant non-HLA antibodies was correlated to renal allograft survival in a nationwide cohort of 4770 recipients transplanted between 1995 and 2006. Autoantibodies against Rho GDP-dissociation inhibitor 2 (ARHGDIB) were significantly associated with graft loss in recipients transplanted with a deceased-donor kidney (N = 3276) but not in recipients of a living-donor kidney (N = 1496). At 10 years after deceased-donor transplantation, recipients with anti-ARHGDIB antibodies (94/3276 = 2.9%) had a 13% lower death-censored covariate-adjusted graft survival compared to the anti-ARHGDIB-negative (3182/3276 = 97.1%) population (hazard ratio 1.82; 95% confidence interval, 1.32-2.53; P = .0003). These antibodies occur independently from donor-specific anti-HLA antibodies (DSA) or other non-HLA antibodies investigated. No significant relations with graft loss were found for the other 13 non-HLA antibodies. We suggest that pretransplant risk assessment can be improved by measuring anti-ARHGDIB antibodies in all patients awaiting deceased-donor transplantation.
Published: 2019

24. Antibodies against ARHGDIB are associated with long-term kidney graft loss

Author: Kamburova, E. G., Gruijters, M.L., Kardol-Hoefnagel, T., Wisse, B. W., Joosten, I. (Irma), Allebes, W.A. (Wil), Meer, A.J.G.M. (Astrid) van der, Hilbrands, L.B., Baas, M. C., Spierings, E. (E.), Hack, C.E. (Erik), van Reekum, F. E., Zuilen, A.D. (Arjan) van, Verhaar, M.C. (Marianne), Bots, M.L. (Michiel), Drop, A., Plaisier, L., Melchers, R.C.A., Seelen, MAJ, Sanders, J.-S. (Jan-Stephan), Hepkema, B.G. (Bouke), Lambeck, AJA, Bungener, LB, Roozendaal, C, Tilanus, M.G.J., Voorter, CE, Wieten, L, van Duijnhoven, E. M., Gelens, M., Christiaans, M.H. (Maarten), Ittersum, F.J. (Frans) van, Nurmohamed, S.A. (Shaikh Azam), Lardy, N.M. (Neubury), Swelsen, W., van der Pant, K., van der Weerd, NC, Berge, I.J.M. (Ineke) ten, Hoitsma, A., van der Boog, P. J. M., Fijter, J.W. (Johan) de, Betjes, M.G.H. (Michiel), Heidt, P.J. (Peter), Roelen, D.L., Claas, FH, Bemelman, F.J. (Fréderike), Otten, H.G. (Henderikus), Kamburova, E. G., Gruijters, M.L., Kardol-Hoefnagel, T., Wisse, B. W., Joosten, I. (Irma), Allebes, W.A. (Wil), Meer, A.J.G.M. (Astrid) van der, Hilbrands, L.B., Baas, M. C., Spierings, E. (E.), Hack, C.E. (Erik), van Reekum, F. E., Zuilen, A.D. (Arjan) van, Verhaar, M.C. (Marianne), Bots, M.L. (Michiel), Drop, A., Plaisier, L., Melchers, R.C.A., Seelen, MAJ, Sanders, J.-S. (Jan-Stephan), Hepkema, B.G. (Bouke), Lambeck, AJA, Bungener, LB, Roozendaal, C, Tilanus, M.G.J., Voorter, CE, Wieten, L, van Duijnhoven, E. M., Gelens, M., Christiaans, M.H. (Maarten), Ittersum, F.J. (Frans) van, Nurmohamed, S.A. (Shaikh Azam), Lardy, N.M. (Neubury), Swelsen, W., van der Pant, K., van der Weerd, NC, Berge, I.J.M. (Ineke) ten, Hoitsma, A., van der Boog, P. J. M., Fijter, J.W. (Johan) de, Betjes, M.G.H. (Michiel), Heidt, P.J. (Peter), Roelen, D.L., Claas, FH, Bemelman, F.J. (Fréderike), and Otten, H.G. (Henderikus)
Abstract: The clinical significance of non‐HLA antibodies on renal allograft survival is a matter of debate, due to differences in reported results and lack of large‐scale studies incorporating analysis of multiple non‐HLA antibodies simultaneously. We developed a multiplex non‐HLA antibody assay against 14 proteins highly expressed in the kidney. In this study, the presence of pretransplant non‐HLA antibodies was correl
Published: 2019
Full Text: View/download PDF

25. Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients

Author: Heidt, P.J. (Peter), Haasnoot, G.W. (Geert), Witvliet, M.D. (Marian), van der Linden-van Oevelen, M.J.H. (Marissa J. H.), Kamburova, E.G., Wisse, B.W., Joosten, I. (Irma), Allebes, W.A. (Wil), van der Meer, A., Hilbrands, L.B. (Luuk), Baas, M.C. (Marije), Spierings, E. (E.), Hack, C.E. (Erik), van Reekum, F., van Zuilen, A.D. (Arjan D.), Verhaar, M.C. (Marianne), Bots, M.L. (Michiel), Drop, A.C.A.D., Plaisier, L., Seelen, M.A.J., Sanders, J.S.F., Hepkema, B.G. (Bouke), Lambeck, A.J.A. (Annechien J.A.), Bungener, L.B., Roozendaal, C., Tilanus, M.G.J. (Marcel), Voorter, C.E.M. (C. E M), Wieten, L., van Duijnhoven, E., Gelens, M., Christiaans, M.H. (Maarten), van Ittersum, F., Nurmohamed, S.A. (Shaikh Azam), Lardy, N.M. (Neubury), Swelsen, W.T., van der Pant, K.A., Weerd, N.C. (Neelke) van der, Berge, I.J.M. (Ineke) ten, Bemelman, F.J. (Fréderike), Hoitsma, A.J. (Andries), van der Boog, P.J.M., Fijter, J.W. (Johan) de, Betjes, M.G.H. (Michiel), Otten, H.G. (Henderikus), Roelen, D.L. (Dave), Claas, F.H.J. (Frans), Heidt, P.J. (Peter), Haasnoot, G.W. (Geert), Witvliet, M.D. (Marian), van der Linden-van Oevelen, M.J.H. (Marissa J. H.), Kamburova, E.G., Wisse, B.W., Joosten, I. (Irma), Allebes, W.A. (Wil), van der Meer, A., Hilbrands, L.B. (Luuk), Baas, M.C. (Marije), Spierings, E. (E.), Hack, C.E. (Erik), van Reekum, F., van Zuilen, A.D. (Arjan D.), Verhaar, M.C. (Marianne), Bots, M.L. (Michiel), Drop, A.C.A.D., Plaisier, L., Seelen, M.A.J., Sanders, J.S.F., Hepkema, B.G. (Bouke), Lambeck, A.J.A. (Annechien J.A.), Bungener, L.B., Roozendaal, C., Tilanus, M.G.J. (Marcel), Voorter, C.E.M. (C. E M), Wieten, L., van Duijnhoven, E., Gelens, M., Christiaans, M.H. (Maarten), van Ittersum, F., Nurmohamed, S.A. (Shaikh Azam), Lardy, N.M. (Neubury), Swelsen, W.T., van der Pant, K.A., Weerd, N.C. (Neelke) van der, Berge, I.J.M. (Ineke) ten, Bemelman, F.J. (Fréderike), Hoitsma, A.J. (Andries), van der Boog, P.J.M., Fijter, J.W. (Johan) de, Betjes, M.G.H. (Michiel), Otten, H.G. (Henderikus), Roelen, D.L. (Dave), and Claas, F.H.J. (Frans)
Abstract: Whereas regular allocation avoids unacceptable mismatches on the donor organ, allocation to highly sensitized patients within the Eurotransplant Acceptable Mismatch (AM) program is based on the patient's HLA phenotype plus acceptable antigens. These are HLA antigens to which the patient never made antibodies, as determined by extensive laboratory testing. AM patients have superior long-term graft survival compared with highly sensitized patients in regular allocation. Here, we questioned whether the AM program also results in lower rejection rates. From the PROCARE cohort, consisting of all Dutch kidney transplants in 1995-2005, we selected deceased donor single transplants with a minimum of 1 HLA mismatch and determined the cumulative 6-month rejection incidence for patients in AM or regular allocation. Additionally, we determined the effect of minimal matching criteria of 1 HLA-B plus 1 HLA-DR, or 2 HLA-DR antigens on rejection incidence. AM patients showed significantly lower rejection rates than highly immunized patients in regular allocation, comparable to nonsensitized patients, independent of other risk factors for rejection. In contrast to highly sensitized patients in regular allocation, minimal matching criteria did not affect rejection rates in AM patients. Allocation based on acceptable antigens leads to relatively low-risk transplants for highly sensitized patients with rejection rates similar to those of nonimmunized individuals.
Published: 2019
Full Text: View/download PDF

26. IN VITRO EVIDENCE FOR DIFFERENTIAL INVOLVEMENT OF CTGF, TGF-β AND PDGF-BB IN MESANGIAL RESPONSE TO INJURY

Author: Blom, I. E., van Dijk, A. J., Wieten, L., Duran, K., Ito, Y., Kleij, L., deNichilo, M., Rabelink, T. J., Weening, J. J., Aten, J., and Goldschmeding, R.
Published: 2001

27. Decreased Graft Survival of Retransplants can Largely be Explained By Increased Hla-immunization

Author: Kamburova, Elena G., Wisse, B. W., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, Eric, Hack, C. E., van Reekum, F., van Zuilen, A. D., Verhaar, M. C., Bots, M. L., Plaisier, L., Seelen, M. A. J., Sanders, J. S. F., Hepkema, B. G., Lambeck, A. J., Bungener, L. B., Roozendaal, C., Tilanus, M. G. J., Voorter, C. E., Wieten, L., van Duijnhoven, E., Gelens, M., Christiaans, M., van Ittersum, F., Nurmohamed, A., Lardy, N. M., Swelsen, W. T., van der Pant, K. A. M. I., van der Weerd, N. C., ten Berge, I. J. M., Bemelman, F. J., Hoitsma, A. J., van der Boog, P. J. M., de Fijter, J. W., Betjes, M. G. H., Heidt, Sebastiaan, Roelen, D. L., Claas, F. H. J., Otten, H. G., Groningen Institute for Organ Transplantation (GIOT), and Groningen Kidney Center (GKC)
Published: 2018

28. PB1741 KIR-LIGAND MISMATCH IS NOT PREDICTIVE FOR LEUKEMIA-FREE SURVIVAL IN PATIENTS WITH FAVORABLE RISK AML AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION.

Author: Van Gelder, M., primary, Billen, E., additional, Voorter, C., additional, Schouten, H., additional, Bos, G., additional, and Wieten, L., additional
Published: 2019
Full Text: View/download PDF

29. PF636 NATURAL KILLER CELL ALLOREACTIVE HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA PATIENTS

Author: Van Elssen, C., primary, Wieten, L., additional, Von dem Borne, P., additional, Nijhof, I., additional, and Meyer, E., additional
Published: 2019
Full Text: View/download PDF

30. Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant

Author: Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., van Reekum, F. E., van Zuilen, A. D., Verhaar, M. C., Bots, M. L., Drop, A. C.A.D., Plaisier, L., Seelen, M. A.J., Sanders, J. S.F., Hepkema, B. G., Lambeck, A. J.A., Bungener, L. B., Roozendaal, C., Tilanus, M. G.J., Voorter, C. E., Wieten, L., van Duijnhoven, E. M., Gelens, M., Christiaans, M. H.L., van Ittersum, F. J., Nurmohamed, S. A., Lardy, N. M., Swelsen, W., van der Pant, K. A., van der Weerd, N. C., ten Berge, I. J.M., Bemelman, F. J., Hoitsma, A., van der Boog, P. J.M., de Fijter, J. W., Betjes, M. G.H., Heidt, S., Roelen, D. L., Claas, F. H., Otten, H. G., Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., van Reekum, F. E., van Zuilen, A. D., Verhaar, M. C., Bots, M. L., Drop, A. C.A.D., Plaisier, L., Seelen, M. A.J., Sanders, J. S.F., Hepkema, B. G., Lambeck, A. J.A., Bungener, L. B., Roozendaal, C., Tilanus, M. G.J., Voorter, C. E., Wieten, L., van Duijnhoven, E. M., Gelens, M., Christiaans, M. H.L., van Ittersum, F. J., Nurmohamed, S. A., Lardy, N. M., Swelsen, W., van der Pant, K. A., van der Weerd, N. C., ten Berge, I. J.M., Bemelman, F. J., Hoitsma, A., van der Boog, P. J.M., de Fijter, J. W., Betjes, M. G.H., Heidt, S., Roelen, D. L., Claas, F. H., and Otten, H. G.
Published: 2018

31. PIRCHE-II is related to graft failure after kidney transplantation

Author: Geneugelijk, K. (Kirsten), Niemann, M. (Matthias), Drylewicz, J. (Julia), van Zuilen, A.D. (Arjan D.), Joosten, I. (Irma), Allebes, W.A. (Wil), van der Meer, A., Hilbrands, L.B. (Luuk), Baas, M.C. (Marije), Hack, C.E. (Erik), van Reekum, F., Verhaar, M.C. (Marianne), Kamburova, E.G., Bots, M.L. (Michiel L.), Seelen, M.A.J., Sanders, J.S.F., Hepkema, B.G. (Bouke), Lambeck, A.J.A. (Annechien J.A.), Bungener, L.B., Roozendaal, C., Tilanus, M.G.J. (Marcel), Vanderlocht, J. (Joris), Voorter, C.E.M. (C. E M), Wieten, L., van Duijnhoven, E., Gelens, M., Christiaans, M.H. (Maarten), van Ittersum, F., Nurmohamed, A., Lardy, J.N.M. (Junior N.M.), Swelsen, W.T., van der Pant, K.A., Weerd, N.C. (Neelke) van der, Berge, I.J.M. (Ineke) ten, Bemelman, F.J. (Fréderike), Hoitsma, A.J. (Andries), van der Boog, P.J.M., Fijter, J.W. (Johan) de, Betjes, M.G.H. (Michiel), Heidt, P.J. (Peter), Roelen, D.L. (Dave), Claas, F.H.J. (Frans), Otten, H.G. (Henderikus), Spierings, E. (E.), Geneugelijk, K. (Kirsten), Niemann, M. (Matthias), Drylewicz, J. (Julia), van Zuilen, A.D. (Arjan D.), Joosten, I. (Irma), Allebes, W.A. (Wil), van der Meer, A., Hilbrands, L.B. (Luuk), Baas, M.C. (Marije), Hack, C.E. (Erik), van Reekum, F., Verhaar, M.C. (Marianne), Kamburova, E.G., Bots, M.L. (Michiel L.), Seelen, M.A.J., Sanders, J.S.F., Hepkema, B.G. (Bouke), Lambeck, A.J.A. (Annechien J.A.), Bungener, L.B., Roozendaal, C., Tilanus, M.G.J. (Marcel), Vanderlocht, J. (Joris), Voorter, C.E.M. (C. E M), Wieten, L., van Duijnhoven, E., Gelens, M., Christiaans, M.H. (Maarten), van Ittersum, F., Nurmohamed, A., Lardy, J.N.M. (Junior N.M.), Swelsen, W.T., van der Pant, K.A., Weerd, N.C. (Neelke) van der, Berge, I.J.M. (Ineke) ten, Bemelman, F.J. (Fréderike), Hoitsma, A.J. (Andries), van der Boog, P.J.M., Fijter, J.W. (Johan) de, Betjes, M.G.H. (Michiel), Heidt, P.J. (Peter), Roelen, D.L. (Dave), Claas, F.H.J. (Frans), Otten, H.G. (Henderikus), and Spierings, E. (E.)
Abstract: Individual HLA mismatches may differentially impact graft survival after kidney transplantation. Therefore, there is a need for a reliable tool to define permissible HLA mismatches in kidney transplantation. We previously demonstrated that donor-derived Predicted Indirectly ReCognizable HLA Epitopes presented by recipient HLA class II (PIRCHE-II) play a role in de novo donor-specific HLA antibodies formation after kidney transplantation. In the present Dutch multi-center study, we evaluated the possible association between PIRCHE-II and kidney graft failure in 2,918 donor-recipient couples that were transplanted between 1995 and 2005. For these donors-recipients couples, PIRCHE-II numbers were related to graft survival in univariate and multivariable analyses. Adjusted for confounders, the natural logarithm of PIRCHE-II was associated with a higher risk for graft failure [hazard ratio (HR): 1.13, 95% CI: 1.04-1.23, p = 0.003]. When analyzing a subgroup of patients who had their first transplantation, the HR of graft failure for ln(PIRCHE-II) was higher compared with the overall cohort (HR: 1.22, 95% CI: 1.10-1.34, p < 0.001). PIRCHE-II demonstrated both early and late effects on graft failure in this subgroup. These data suggest that the PIRCHE-II may impact graft survival after kidney transplantation. Inclusion of PIRCHE-II in donor-selection criteria may eventually lead to an improved kidney graft survival.
Published: 2018
Full Text: View/download PDF

32. Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure

Author: Kamburova, E.G., Wisse, B.W., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., Reekum, F.E. van, Zuilen, A.D. van, Verhaar, M.C., Bots, M.L., Drop, A.C., Plaisier, L., Seelen, M.A., Sanders, J.S., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M.A., Christiaans, M.H., Ittersum, F.J. van, Nurmohamed, S.A., Lardy, N.M., Swelsen, W., Pant, Karlijn A.M.I. van der, Weerd, N.C. van der, Berge, I.J. Ten, Bemelman, F.J., Hoitsma, A.J., Boog, P.J. van der, Fijter, J.W. de, Betjes, M.G., Heidt, S., Roelen, D.L., Claas, F.H., Otten, H.G., Kamburova, E.G., Wisse, B.W., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., Reekum, F.E. van, Zuilen, A.D. van, Verhaar, M.C., Bots, M.L., Drop, A.C., Plaisier, L., Seelen, M.A., Sanders, J.S., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M.A., Christiaans, M.H., Ittersum, F.J. van, Nurmohamed, S.A., Lardy, N.M., Swelsen, W., Pant, Karlijn A.M.I. van der, Weerd, N.C. van der, Berge, I.J. Ten, Bemelman, F.J., Hoitsma, A.J., Boog, P.J. van der, Fijter, J.W. de, Betjes, M.G., Heidt, S., Roelen, D.L., Claas, F.H., and Otten, H.G.
Abstract: Item does not contain fulltext
Published: 2018

33. Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant

Author: CTI Otten, Infection & Immunity, CDL Celdiagnostiek, CTI, MS Nefrologie, Circulatory Health, Nefro Vasculaire Geneeskunde, Regenerative Medicine and Stem Cells, Cardiovasculaire Epi Team 5, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, MS Mondziekten/Kaakchirurgie, Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., van Reekum, F. E., van Zuilen, A. D., Verhaar, M. C., Bots, M. L., Drop, A. C.A.D., Plaisier, L., Seelen, M. A.J., Sanders, J. S.F., Hepkema, B. G., Lambeck, A. J.A., Bungener, L. B., Roozendaal, C., Tilanus, M. G.J., Voorter, C. E., Wieten, L., van Duijnhoven, E. M., Gelens, M., Christiaans, M. H.L., van Ittersum, F. J., Nurmohamed, S. A., Lardy, N. M., Swelsen, W., van der Pant, K. A., van der Weerd, N. C., ten Berge, I. J.M., Bemelman, F. J., Hoitsma, A., van der Boog, P. J.M., de Fijter, J. W., Betjes, M. G.H., Heidt, S., Roelen, D. L., Claas, F. H., Otten, H. G., CTI Otten, Infection & Immunity, CDL Celdiagnostiek, CTI, MS Nefrologie, Circulatory Health, Nefro Vasculaire Geneeskunde, Regenerative Medicine and Stem Cells, Cardiovasculaire Epi Team 5, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, MS Mondziekten/Kaakchirurgie, Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., van Reekum, F. E., van Zuilen, A. D., Verhaar, M. C., Bots, M. L., Drop, A. C.A.D., Plaisier, L., Seelen, M. A.J., Sanders, J. S.F., Hepkema, B. G., Lambeck, A. J.A., Bungener, L. B., Roozendaal, C., Tilanus, M. G.J., Voorter, C. E., Wieten, L., van Duijnhoven, E. M., Gelens, M., Christiaans, M. H.L., van Ittersum, F. J., Nurmohamed, S. A., Lardy, N. M., Swelsen, W., van der Pant, K. A., van der Weerd, N. C., ten Berge, I. J.M., Bemelman, F. J., Hoitsma, A., van der Boog, P. J.M., de Fijter, J. W., Betjes, M. G.H., Heidt, S., Roelen, D. L., Claas, F. H., and Otten, H. G.
Published: 2018

34. Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant

Author: Kamburova, E G, Wisse, B W, Joosten, I, Allebes, WA, Meer, A, Hilbrands, LB, Baas, M C, Spierings, E, Hack, CE, van Reekum, F E, van Zuilen, AD, Verhaar, MC, Bots, ML, Drop, A, Plaisier, L, Seelen, MAJ, Sanders, JSF, Hepkema, BG, Lambeck, AJA, Bungener, LB, Roozendaal, C, Tilanus, MGJ, Voorter, CE, Wieten, L, van Duijnhoven, E M, Gelens, M, Christiaans, MHL, van Ittersum, FJ, Nurmohamed, SA, Lardy, NM, Swelsen, W, van der Pant, K A, van der Weerd, NC, ten Berge, IJM, Bemelman, FJ, Hoitsma, A, van der Boog, P J M, de Fijter, JW, Betjes, M.G.H., Heidt, S, Roelen, DL, Claas, FH, Otten, HG, Kamburova, E G, Wisse, B W, Joosten, I, Allebes, WA, Meer, A, Hilbrands, LB, Baas, M C, Spierings, E, Hack, CE, van Reekum, F E, van Zuilen, AD, Verhaar, MC, Bots, ML, Drop, A, Plaisier, L, Seelen, MAJ, Sanders, JSF, Hepkema, BG, Lambeck, AJA, Bungener, LB, Roozendaal, C, Tilanus, MGJ, Voorter, CE, Wieten, L, van Duijnhoven, E M, Gelens, M, Christiaans, MHL, van Ittersum, FJ, Nurmohamed, SA, Lardy, NM, Swelsen, W, van der Pant, K A, van der Weerd, NC, ten Berge, IJM, Bemelman, FJ, Hoitsma, A, van der Boog, P J M, de Fijter, JW, Betjes, M.G.H., Heidt, S, Roelen, DL, Claas, FH, and Otten, HG
Abstract: The presence of donor-specific anti-HLA antibodies (DSAs) is associated with increased risk of graft failure after kidney transplant. We hypothesized that DSAs against HLA class I, class II, or both classes indicate a different risk for graft loss between deceased and living donor transplant. In this study, we investigated the impact of pretransplant DSAs, by using single antigen bead assays, on long-term graft survival in 3237 deceased and 1487 living donor kidney transplants with a negative complement-dependent crossmatch. In living donor transplants, we found a limited effect on graft survival of DSAs against class I or II antigens after transplant. Class I and II DSAs combined resulted in decreased 10-year graft survival (84% to 75%). In contrast, after deceased donor transplant, patients with class I or class II DSAs had a 10-year graft survival of 59% and 60%, respectively, both significantly lower than the survival for patients without DSAs (76%). The combination of class I and II DSAs resulted in a 10-year survival of 54% in deceased donor transplants. In conclusion, class I and II DSAs are a clear risk factor for graft loss in deceased donor transplants, while in living donor transplants, class I and II DSAs seem to be associated with an increased risk for graft failure, but this could not be assessed due to their low prevalence.
Published: 2018

35. PIRCHE-II: A NOVEL TOOL TO IDENTIFY PERMISSIBLE HLA MISMATCHES IN KIDNEY TRANSPLANTATION

Author: Geneugelijk, K., Niemann, M., Drylewicz, J., Zuilen, A.D. van, Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Hack, C.E., Reekum, F.E. van, Verhaar, M., Kamburova, E.G., Bots, M.L., Seelen, M.A.J., Sanders, J.S.F., Hepkema, B.G., Lambeck, A.J., Bungener, L.B., Roozendaal, C., Tilanus, M.G.J., Vanderlocht, J., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H.L., Ittersum, F.J. van, Nurmohamed, A., Lardy, N.M., Swelsen, W., Pant, K.A. van der, Weerd, N.C. van der, Berge, I.J.M. ten, Bemelman, F.D.J., Hoitsma, A., Boog, P.J.M. van der, Fijter, J.W. de, Betjes, M.G.H., Heidt, S., Roelen, D.L., Claas, F.H.J., Otten, H.G., and Spierings, E.
Published: 2017

36. DIFFERENTIAL EFFECT OF DONOR-SPECIFIC HLA ANTIBODIES IN LIVING VERSUS DECEASED DONOR KIDNEY TRANSPLANTATION

Author: Kamburova, E.G., Wisse, B.W., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., Reekum, F. van, Zuilen, A. van, Verhaar, M.C., Bots, M.L., Drop, A.C.A.D., Plaisier, L., Seelen, M.A.J., Sanders, J.S.F., Hepkema, B.G., Lambeck, A.J., Bungener, L.B., Roozendaal, C., Tilanus, M.G.J., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H.L., Ittersum, F.J. van, Nurmohamed, A., Lardy, N.M., Swelsen, W., Pant, K.A. van der, Weerd, N.C. van der, Berge, I.J.M. ten, Bemelman, F.J., Hoitsma, A., Boog, P.J.M. van der, Fijter, H. de, Betjes, M.G.H., Heidt, S., Roelen, D.L., Claas, F.H.J., and Otten, H.G.
Published: 2017

37. How can we reduce costs of solid-phase multiplex-bead assays used to determine anti-HLA antibodies?

Author: Kamburova, E.G., Wisse, B.W., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., Reekum, F.E. van, Zuilen, A.D. van, Verhaar, M., Bots, M.L., Drop, A.C.A.D., Plaisier, L., Seelen, M.A.J., Sanders, J.S.F., Hepkema, B.G., Lambeck, A.J., Bungener, L.B., Roozendaal, C., Tilanus, M.G.J., Vanderlocht, J., Voorter, C.E., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H.L., Ittersum, F.J. van, Nurmohamed, A., Lardy, N.M., Swelsen, W., Pant, K.A. van der, Weerd, N.C. van der, Berge, I.J.M. ten, Bemelman, F.J., Hoitsma, A., Boog, P.J.M. van der, Fijter, J.W. de, Betjes, M.G.H., Heidt, S., Roelen, D.L., Claas, F.H., Otten, H.G., RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: DA Transplantatie Immunologie (5), MUMC+: DA TI Staf (9), MUMC+: DA TI Laboratorium (9), MUMC+: MA Nefrologie (9), RS: NUTRIM - R3 - Chronic inflammatory disease and wasting, Internal medicine, Nephrology, ICaR - Ischemia and repair, Internal Medicine, Other departments, AII - Amsterdam institute for Infection and Immunity, Groningen Institute for Organ Transplantation (GIOT), and Groningen Kidney Center (GKC)
Subjects: CLINICAL-RELEVANCE, KIDNEY-TRANSPLANTATION, Immunology, Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], Sensitivity and Specificity, HLA Antigens, Isoantibodies, Genetics, Journal Article, Immunology and Allergy, Humans, Alleles, Automation, Laboratory, Immunoassay, Observer Variation, ALLOANTIBODIES, Histocompatibility Testing, Immune Sera, Reproducibility of Results, human leukocyte antigen antibodies, Kidney Transplantation, single antigen, solid-phase multiplex-bead assays, luminex, Reagent Kits, Diagnostic, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]
Abstract: Item does not contain fulltext Solid-phase multiplex-bead assays are widely used in transplantation to detect anti-human leukocyte antigen (HLA) antibodies. These assays enable high resolution detection of low levels of HLA antibodies. However, multiplex-bead assays are costly and yield variable measurements that limit the comparison of results between laboratories. In the context of a Dutch national Consortium study we aimed to determine the inter-assay and inter-machine variability of multiplex-bead assays, and we assessed how to reduce the assay reagents costs. Fifteen sera containing a variety of HLA antibodies were used yielding in total 7092 median fluorescence intensities (MFI) values. The inter-assay and inter-machine mean absolute relative differences (MARD) of the screening assay were 12% and 13%, respectively. The single antigen bead (SAB) inter-assay MARD was comparable, but showed a higher lot-to-lot variability. Reduction of screening assay reagents to 50% or 40% of manufacturers' recommendations resulted in MFI values comparable to 100% of the reagents, with an MARD of 12% or 14%, respectively. The MARD of the 50% and 40% SAB assay reagent reductions were 11% and 22%, respectively. From this study, we conclude that the reagents can be reliably reduced at least to 50% of manufacturers' recommendations with virtually no differences in HLA antibody assignments.
Published: 2016
Full Text: View/download PDF

38. PRE-TRANSPLANT DONOR SPECIFIC HLA ANTIBODIES IN 4386 RENAL TRANSPLANT RECIPIENTS: A PRELIMINARY ANALYSIS OF THE PROCARE COHORT

Author: Kamburova, E.G., Wisse, B.W., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., Reekum, F. van, Zuilen, A.D. van, Verhaar, M.C., Bots, M.L., Drop, A.C.A.D., Plaisier, L., Seelen, M.A.J., Sanders, J.S.F., Hepkema, B.G., Lambeck, A.J., Bungener, L.B., Roozendaal, C., Tilanus, M.G.J., Vanderlocht, J., Voorter, C.E., Wieten, L., Duijnhoven, E. van, Gelens, M., Christiaans, M., Ittersum, F. van, Nurmohamed, A., Lardy, N.M., Swelsen, W.T., Pant, K.A.M.I. van der, Weerd, N.C. van der, Berge, I.J.M. ten, Bemelman, F.J., Hoitsma, A.J., Fijter, J.W. de, Betjes, M.G.H., Roelen, D.L., Claas, F.H.J., and Otten, H.G.
Published: 2016

39. How can we reduce costs of solid-phase multiplex-bead assays used to determine anti-HLA antibodies?

Author: Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., van Reekum, F. E., van Zuilen, A. D., Verhaar, M., Bots, M. L., Drop, A. C A D, Plaisier, L., Seelen, M. A J, Sanders, J. S F, Hepkema, B. G., Lambeck, A. J., Bungener, L. B., Roozendaal, C., Tilanus, M. G J, Vanderlocht, J., Voorter, C. E., Wieten, L., van Duijnhoven, E. M., Gelens, M., Christiaans, M. H L, van Ittersum, F. J., Nurmohamed, A., Lardy, N. M., Swelsen, W., van der Pant, K. A., van der Weerd, N. C., ten Berge, I. J M, Bemelman, F. J., Hoitsma, A., van der Boog, P. J M, de Fijter, J. W., Betjes, M. G H, Heidt, S., Roelen, D. L., Claas, F. H., Otten, H. G., Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., van Reekum, F. E., van Zuilen, A. D., Verhaar, M., Bots, M. L., Drop, A. C A D, Plaisier, L., Seelen, M. A J, Sanders, J. S F, Hepkema, B. G., Lambeck, A. J., Bungener, L. B., Roozendaal, C., Tilanus, M. G J, Vanderlocht, J., Voorter, C. E., Wieten, L., van Duijnhoven, E. M., Gelens, M., Christiaans, M. H L, van Ittersum, F. J., Nurmohamed, A., Lardy, N. M., Swelsen, W., van der Pant, K. A., van der Weerd, N. C., ten Berge, I. J M, Bemelman, F. J., Hoitsma, A., van der Boog, P. J M, de Fijter, J. W., Betjes, M. G H, Heidt, S., Roelen, D. L., Claas, F. H., and Otten, H. G.
Published: 2016

40. How can we reduce costs of solid-phase multiplex-bead assays used to determine anti-HLA antibodies?

Author: CTI Otten, Infection & Immunity, CDL Celdiagnostiek, CTI, Lab exp immunologie / biomarkers ontst., MS Nefrologie, Circulatory Health, Nefro Vasculaire Geneeskunde, Regenerative Medicine and Stem Cells, Cardiovasculaire Epi Team 5, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., van Reekum, F. E., van Zuilen, A. D., Verhaar, M., Bots, M. L., Drop, A. C A D, Plaisier, L., Seelen, M. A J, Sanders, J. S F, Hepkema, B. G., Lambeck, A. J., Bungener, L. B., Roozendaal, C., Tilanus, M. G J, Vanderlocht, J., Voorter, C. E., Wieten, L., van Duijnhoven, E. M., Gelens, M., Christiaans, M. H L, van Ittersum, F. J., Nurmohamed, A., Lardy, N. M., Swelsen, W., van der Pant, K. A., van der Weerd, N. C., ten Berge, I. J M, Bemelman, F. J., Hoitsma, A., van der Boog, P. J M, de Fijter, J. W., Betjes, M. G H, Heidt, S., Roelen, D. L., Claas, F. H., Otten, H. G., CTI Otten, Infection & Immunity, CDL Celdiagnostiek, CTI, Lab exp immunologie / biomarkers ontst., MS Nefrologie, Circulatory Health, Nefro Vasculaire Geneeskunde, Regenerative Medicine and Stem Cells, Cardiovasculaire Epi Team 5, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., van Reekum, F. E., van Zuilen, A. D., Verhaar, M., Bots, M. L., Drop, A. C A D, Plaisier, L., Seelen, M. A J, Sanders, J. S F, Hepkema, B. G., Lambeck, A. J., Bungener, L. B., Roozendaal, C., Tilanus, M. G J, Vanderlocht, J., Voorter, C. E., Wieten, L., van Duijnhoven, E. M., Gelens, M., Christiaans, M. H L, van Ittersum, F. J., Nurmohamed, A., Lardy, N. M., Swelsen, W., van der Pant, K. A., van der Weerd, N. C., ten Berge, I. J M, Bemelman, F. J., Hoitsma, A., van der Boog, P. J M, de Fijter, J. W., Betjes, M. G H, Heidt, S., Roelen, D. L., Claas, F. H., and Otten, H. G.
Published: 2016

41. Regulatory T cells that recognize a ubiquitous stress-inducible self-antigen are long-lived suppressors of autoimmune arthritis

Author: van Herwijnen, M.J.C., Wieten, L., van der Zee, R., van Kooten, P.J., Wagenaar, J.P.A., Hoek, A., den Braber, A.J., Anderton, S.M., Singh, M., Meiring, H.D., van Els, C.A.C.M., van Eden, W., Broere, F., Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, Dep Infectieziekten Immunologie, Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, and Dep Infectieziekten Immunologie
Subjects: medicine.medical_treatment, Epitopes, T-Lymphocyte, chemical and pharmacologic phenomena, Autoimmunity, Biology, Lymphocyte Activation, medicine.disease_cause, Autoantigens, Immunotherapy, Adoptive, T-Lymphocytes, Regulatory, Epitope, Autoimmune Diseases, Mice, 03 medical and health sciences, 0302 clinical medicine, Antigen, Stress, Physiological, Immune Tolerance, medicine, Animals, HSP70 Heat-Shock Proteins, IL-2 receptor, Administration, Intranasal, 030304 developmental biology, Mice, Inbred BALB C, 0303 health sciences, MHC class II, Multidisciplinary, Arthritis, FOXP3, Immunotherapy, Biological Sciences, International (not English), Adoptive Transfer, 3. Good health, Arthritis therapy, Immunology, biology.protein, Immunization, 030215 immunology
Abstract: Reestablishing self-tolerance in autoimmunity is thought to depend on self-reactive regulatory T cells (Tregs). Exploiting these antigen-specific regulators is hampered by the obscure nature of disease-relevant autoantigens. We have uncovered potent disease-suppressive Tregs recognizing Heat Shock Protein (Hsp) 70 self-antigens, enabling selective activity in inflamed tissues. Hsp70 is a major contributor to the MHC class II ligandome. Here we show that a conserved Hsp70 epitope (B29) is present in murine MHC class II and that upon transfer, B29-induced CD4 + CD25 + Foxp3 + T cells suppress established proteoglycan-induced arthritis in mice. These self-antigen–specific Tregs were activated in vivo, and when using Lymphocyte Activation Gene-3 as a selection marker, as few as 4,000 cells sufficed. Furthermore, depletion of transferred Tregs abrogated disease suppression. Transferred cells exhibited a stable phenotype and were found in joints and draining lymph nodes up to 2 mo after transfer. Given that ( i ) B29 administration by itself suppressed disease, ( ii ) our findings were made with wild-type (T-cell receptor nontransgenic) Tregs, and ( iii ) the B29 human homolog is presented by HLA class II, we are nearing translation of antigen-specific Treg activation as a promising intervention for chronic inflammatory diseases.
Published: 2012

42. RNA and protein expression of HLA-A∗23:19Q

Author: Gerritsen, K.E.H., primary, Voorter, C.E.M., additional, Joannes, M.O.R.F., additional, Senden-Gijsbers, B.L.M.G., additional, Agis, F., additional, Wieten, L., additional, and Tilanus, M.G.J., additional
Published: 2015
Full Text: View/download PDF

43. Hsp70 expression and induction as a readout for detection of immune modulatory components in food

Author: Wieten, L., van der Zee, R., Goedemans, R., Sijtsma, J., Serafini, M., Lubsen, N.H., van Eden, W., Broere, F., Risk Assessment of Toxic and Immunomodulatory Agents, and Dep Infectieziekten Immunologie
Published: 2010

44. The PROCARE consortium: Toward an improved allocation strategy for kidney allografts

Author: Otten, H.G., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M., Spierings, E., Hack, C.E., Reekum, F. van, Zuilen, A.D. van, Verhaar, M.C., Bots, M.L., Seelen, M.A., Sanders, J.S., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G.J., Vanderlocht, J., Voorter, C.E.M., Wieten, L., Duijnhoven, E. van, Gelens, M., Christiaans, M., Ittersum, F. van, Nurmohamed, A., Lardy, N.M., Swelsen, W.T., Donselaar-van Pant, K.A., Weerd, N.C. van der, Berge, I.J. Ten, Bemelman, F.J., Hoitsma, A.J., Fijter, J.W. de, Betjes, M.G., Roelen, D.L., Claas, F.H., Otten, H.G., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M., Spierings, E., Hack, C.E., Reekum, F. van, Zuilen, A.D. van, Verhaar, M.C., Bots, M.L., Seelen, M.A., Sanders, J.S., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G.J., Vanderlocht, J., Voorter, C.E.M., Wieten, L., Duijnhoven, E. van, Gelens, M., Christiaans, M., Ittersum, F. van, Nurmohamed, A., Lardy, N.M., Swelsen, W.T., Donselaar-van Pant, K.A., Weerd, N.C. van der, Berge, I.J. Ten, Bemelman, F.J., Hoitsma, A.J., Fijter, J.W. de, Betjes, M.G., Roelen, D.L., and Claas, F.H.
Abstract: Item does not contain fulltext, Kidney transplantation is the best treatment option for patients with end-stage renal failure. At present, approximately 800 Dutch patients are registered on the active waiting list of Eurotransplant. The waiting time in the Netherlands for a kidney from a deceased donor is on average between 3 and 4years. During this period, patients are fully dependent on dialysis, which replaces only partly the renal function, whereas the quality of life is limited. Mortality among patients on the waiting list is high. In order to increase the number of kidney donors, several initiatives have been undertaken by the Dutch Kidney Foundation including national calls for donor registration and providing information on organ donation and kidney transplantation. The aim of the national PROCARE consortium is to develop improved matching algorithms that will lead to a prolonged survival of transplanted donor kidneys and a reduced HLA immunization. The latter will positively affect the waiting time for a retransplantation. The present algorithm for allocation is among others based on matching for HLA antigens, which were originally defined by antibodies using serological typing techniques. However, several studies suggest that this algorithm needs adaptation and that other immune parameters which are currently not included may assist in improving graft survival rates. We will employ a multicenter-based evaluation on 5429 patients transplanted between 1995 and 2005 in the Netherlands. The association between key clinical endpoints and selected laboratory defined parameters will be examined, including Luminex-defined HLA antibody specificities, T and B cell epitopes recognized on the mismatched HLA antigens, non-HLA antibodies, and also polymorphisms in complement and Fc receptors functionally associated with effector functions of anti-graft antibodies. From these data, key parameters determining the success of kidney transplantation will be identified which will lead to the identification
Published: 2014

45. Endogenous stress proteins as targets for anti-inflammatory T cells

Author: Wieten, L., Strategic Infection Biology, Dep Infectieziekten Immunologie, van Eden, Willem, van der Zee, Ruurd, and Broere, Femke
Abstract: Stress proteins such as heat shock proteins (Hsp) are important controllers of both cellular and immune homeostasis. Enhanced Hsp expression can be observed in virtually every inflammatory condition and has been proposed by us and others to lead to local activation of Hsp-specific anti-inflammatory T cells. Amongst the various Hsp, particularly Hsp70 is highly stress inducible. But stress inducibility of Hsp70 is decreased at increasing age. Therefore, we hypothesized in this thesis that when expression of the self-antigen is reduced, Hsp mediated immunoregulation fails and that boosting either Hsp-specific T cell responses or HSP expression itself, can restore or enhance immune homeostasis. First we explored in in vitro systems if the immune system can actually respond to enhanced Hsp70 levels. Using flow cytometry, Hsp70-specific CD4+ T cell hybridomas and reporter cell lines we found that Hsp70 is highly stress inducible in immune cells and that Hsp70-specific T cells can recognize enhanced Hsp70 expression. Furthermore, this strategy yielded the identity of several new food-derived enhancers of stress-induced Hsp70 expression, amongst them carvacrol, found in thyme and oregano. Then we proceeded to investigate the effect of boosting Hsp70-specific T cell responses with exogenous Hsp70 in the proteoglycan-induced arthritis (PGIA model). We demonstrate that intraperitoneal immunization with mycobacterial (Mt) Hsp70 suppresses PGIA. Moreover, we provide evidence for the mechanism of Hsp-specific regulatory T cells by our finding that IL-10 is essential for suppression. Since mucosal antigen administration will be an appealing way of tolerance induction, we studied the cellular basis of mucosal tolerance in the PGIA model and confirmed that also nasal administration of Mt Hsp70 ameliorates PGIA. Subsequently, the immunodominant T cell epitopes of Mt Hsp70 were identified. One of the highly conserved epitopes (peptide C1) was found to induce IL-10 and to suppress PGIA upon intranasal administration. We uncovered in addition, that this peptide is a good binder (in silico) to the human HLA and that human CD4+ T cell can recognize the peptide, illustrating the relevance for clinical application in humans. To boost Hsp70 expression directly, Hsp70 levels were manipulated with the food constituent carvacrol. Carvacrol potently enhanced stress-induced Hsp70 expression both in vitro and upon intragastric administration in vivo. Up-regulation of Hsp70 was sensed by Hsp70-specific T cell hybridomas. Also in vivo we show that carvacrol enhances Hsp70-specific T cell responses. Subsequently, intragastric administration of carvacrol suppressed PGIA and this protection could be transferred to naïve recipients with T cells, thus providing the first evidence that boosting endogenous Hsp can be translated into immune regulation. Furthermore, this data demonstrate that enhancing immune fitness through food components such as carvacrol is feasible and would allow relatively easy and safe intervention means. In summary the findings presented in this thesis show that boosting Hsp70 expression or the Hsp70-specific T cell response can modulate the immune system and enhance immune homeostasis, thereby illustrating that endogenous Hsp can function as targets for anti-inflammatory T cells, which will contribute to development of new or refinement of existing intervention strategies to treat autoimmune disease.
Published: 2009

46. IL-10 is critically involved in mycobacterial HSP70 induced suppression of proteoglycan-induced arthritis

Author: Wieten, L., Berlo, S.E., ten Brink, C.B.M., van Kooten, P.J., Singh, M., van der Zee, R., Glant, T., Broere, F., van Eden, W., Risk Assessment of Toxic and Immunomodulatory Agents, and Dep Infectieziekten Immunologie
Subjects: Econometric and Statistical Methods: General, Geneeskunde (GENK), Geneeskunde(GENK)
Published: 2009

47. Cell stress induced HSP are targets of regulatory T cells: a role for HSP inducing compounds as anti-inflammatory immuno-modulators?

Author: Wieten, L., Hauet-Broere, F., van der Zee, R., Klein Koerkamp, E., Wagenaar-Hilbers, J.P.A., van Eden, W., Risk Assessment of Toxic and Immunomodulatory Agents, and Dep Infectieziekten Immunologie
Published: 2007

48. The Maastricht Transplant Center: Clinical setting and epitope searches in HLA class II molecules: Does the structural localization of a polymorphic site contribute to its immunogenicity?

Author: Schellekens, J., primary, Vanderlocht, J., additional, Groeneweg, M., additional, Voorter, C.E., additional, Wieten, L., additional, Gelens, M.A., additional, van Duijnhoven, E.M., additional, van Heurn, L.W.E., additional, Christiaans, M.H.L., additional, and Tilanus, M.G.J., additional
Published: 2014
Full Text: View/download PDF

49. The PROCARE consortium: Toward an improved allocation strategy for kidney allografts

Author: Otten, H.G., primary, Joosten, I., additional, Allebes, W.A., additional, van der Meer, A., additional, Hilbrands, L.B., additional, Baas, M., additional, Spierings, E., additional, Hack, C.E., additional, van Reekum, F., additional, van Zuilen, A.D., additional, Verhaar, M.C., additional, Bots, M.L., additional, Seelen, M.A.J., additional, Sanders, J.S.F., additional, Hepkema, B.G., additional, Lambeck, A.J., additional, Bungener, L.B., additional, Roozendaal, C., additional, Tilanus, M.G.J., additional, Vanderlocht, J., additional, Voorter, C.E., additional, Wieten, L., additional, van Duijnhoven, E., additional, Gelens, M., additional, Christiaans, M., additional, van Ittersum, F., additional, Nurmohamed, A., additional, Lardy, N.M., additional, Swelsen, W.T., additional, van Donselaar-van der Pant, K.A.M.I., additional, van der Weerd, N.C., additional, ten Berge, I.J.M., additional, Bemelman, F.J., additional, Hoitsma, A.J., additional, de Fijter, J.W., additional, Betjes, M.G.H., additional, Roelen, D.L., additional, and Claas, F.H.J., additional
Published: 2014
Full Text: View/download PDF

50. Differential effects of donor‐specific HLAantibodies in living versus deceased donor transplant

Author: Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., Reekum, F. E., Zuilen, A. D., Verhaar, M. C., Bots, M. L., Drop, A. C. A. D., Plaisier, L., Seelen, M. A. J., Sanders, J. S .F., Hepkema, B. G., Lambeck, A. J. A., Bungener, L. B., Roozendaal, C., Tilanus, M. G. J., Voorter, C. E., Wieten, L., Duijnhoven, E. M., Gelens, M., Christiaans, M. H. L., Ittersum, F. J., Nurmohamed, S. A., Lardy, N. M., Swelsen, W., Pant, K. A., Weerd, N. C., Berge, I. J. M., Bemelman, F. J., Hoitsma, A., Boog, P. J. M., Fijter, J. W., Betjes, M. G. H., Heidt, S., Roelen, D. L., Claas, F. H., and Otten, H. G.
Abstract: The presence of donor‐specific anti‐HLAantibodies (DSAs) is associated with increased risk of graft failure after kidney transplant. We hypothesized that DSAsagainst HLAclass I, class II,or both classes indicate a different risk for graft loss between deceased and living donor transplant. In this study, we investigated the impact of pretransplant DSAs, by using single antigen bead assays, on long‐term graft survival in 3237 deceased and 1487 living donor kidney transplants with a negative complement‐dependent crossmatch. In living donor transplants, we found a limited effect on graft survival of DSAsagainst class I or IIantigens after transplant. Class I and II DSAscombined resulted in decreased 10‐year graft survival (84% to 75%). In contrast, after deceased donor transplant, patients with class I or class II DSAshad a 10‐year graft survival of 59% and 60%, respectively, both significantly lower than the survival for patients without DSAs(76%). The combination of class I and II DSAsresulted in a 10‐year survival of 54% in deceased donor transplants. In conclusion, class I and II DSAsare a clear risk factor for graft loss in deceased donor transplants, while in living donor transplants, class I and II DSAsseem to be associated with an increased risk for graft failure, but this could not be assessed due to their low prevalence. Via a retrospective multicenter study, the authors investigate the impact of pretransplant donor‐specific HLA antibodies on long‐term graft survival in deceased and living donor kidney transplantations.
Published: 2018
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

227 results on '"Wieten, L."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources